MuSK antibody-positive MG patients often present with a severe clinical course and higher dosages of immunosuppressants are required for their management [2], prompting the innovation of novel therapeutic reagents with specific mechanisms of action and fewer side effects. Here, MUSK is linked to myasthenia gravis.